Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment
The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.
‘Practice Changing’ Results Hint at New Adjuvant Therapy Treatment Options
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 September 2017 In Treatment
Adjuvant treatment is used in addition to tumor removal e.g. via surgery or radiotherapy to help delay or prevent the recurrence of melanoma. It is often recommended for high-risk melanoma (defined as melanoma deeper or thicker than 4mm thick at the primary site or involves nearby lymph nodes). Approved adjuvant therapies in melanoma include interferon and, more recently, ipilimumab. But neither of these approaches is wholly satisfying since relatively few patients appear to benefit and side-effects are a major factor.
Melanoma Survivor and Pro Baseball Hall of Famer Mike Schmidt Shares His “Game Plan” for Battling Cancer
Mike Schmidt, member of the Baseball Hall of Fame, is considered to be the greatest third baseman of all-time. As a professional athlete, he always felt invincible, but in 2013 a melanoma diagnosis threw him a curveball that he wasn’t prepared for.
Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment
While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?
Melanoma Clinical Oncology Research: Interview with Dr. Joshua Arbesman
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 6 June 2017 In Science, Treatment
As a third year medical student, MD Candidate Pooja Rambhia had the privilege of conducting an elective research year under Dr. Joshua Arbesman’s mentorship at University Hospitals Cleveland Medical Center. Arbesman has a unique role in translational basic science research within the realm of familial melanoma.
What Gut Bacteria Tell Us About Treating Melanoma and Other Cancers
Despite success in the use of immunotherapy to treat cancer by harnessing the body’s immune system to fight it, a major difficulty continues to be the range of responses to treatment among patients. It’s why researchers are exploring why some cancer patients exhibit astounding results with little side effects while others receive no benefits to the treatment and/or experience severe side effects.
Taking Charge of the Skin You’re In: 3 Levels of Melanoma Prevention and Detection
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 3 April 2017 In Melanoma Stories, Prevention, Treatment
No healthy person in their twenties expects they’re going to get a call one day telling them they have an invasive nodular melanoma. Despite seeing and hearing of horrible stories about young patients developing cancers, we can’t imagine it’ll happen to us. That element of surprise is exactly what 25-year-old medical student, Alissa Prior, experienced upon hearing her diagnosis.
The Power of Combination Therapies: One Patient’s Road to Remission
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment
Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.
Research Q&A: Dr. Tim Bullock
21 March 2016 In Science
In the latest blog post, we chatted with the University of Virginia’s Tim Bullock, Ph.D., a tumor immunologist in the Pathology Department and MRA-funded investigator. Read on to learn what he has to say about melanoma research and prevention efforts.
Cancer’s Week in the Spotlight
Cancer has been in the news a lot this week. We learned that two pop-culture artists – David Bowie and Alan Rickman – lost their battles with cancer. It’s a stark contrast to the news we heard last month about President Jimmy Carter, who has had a positive treatment response...